文献速递细菌感染、耐药与抗菌药物

累积抗生素暴露与尿源性革兰阴性菌血症中头孢曲松耐药相关

Cumulative Antibiotic Exposure Is Associated With Ceftriaxone Resistance Among Patients With Urinary Source Gram-negative Bloodstream Infection: A Retrospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

回顾性队列研究纳入721例尿源性单微生物革兰阴性菌血症成人患者,其中70例(9.7%)为头孢曲松耐药(CRO-R)病原,651例(90.3%)为头孢曲松敏感(CRO-S)病原。CRO-R组BSI前12个月抗生素DOT、mASI和DASC均显著高于CRO-S组(P < .001),且CRO-R组从血培养采集到适当抗生素治疗的中位时间显著更长(24小时 vs 1小时,P < .001)。

要点

  • 尿源性革兰阴性菌血症中CRO-R占9.7%,其BSI前1年累积抗生素暴露显著高于CRO-S。
  • CRO-R组从血培养采集到适当抗生素治疗的中位时间24小时,显著长于CRO-S组的1小时。
  • BSI前累积抗生素治疗(以mASI量化)增加与BSI后1年CDI风险显著相关(P = .027)。

核心结论

  • 首次发作的CRO-R肠杆菌科BSI患者较CRO-S患者有显著更高的既往抗生素暴露,并经历适当治疗的显著延迟。

研究设计与样本

  • 回顾性队列研究,纳入2019年5月至2023年5月在Mayo Clinic初级保健的成人患者,首次发作的尿源性单微生物大肠埃希菌、肺炎克雷伯菌、产酸克雷伯菌或奇异变形杆菌BSI,共721例。

主要发现

  • CRO-R组70例(9.7%),CRO-S组651例(90.3%)。
  • BSI前12个月,CRO-R组抗生素DOT、mASI和DASC均显著高于CRO-S组(P < .001)。
  • CRO-R组从血培养采集到适当抗生素治疗的中位时间为24小时(IQR 16-48),CRO-S组为1小时(IQR 0-2),差异显著(P < .001)。
  • BSI前累积抗生素治疗(以mASI量化)增加与BSI后1年CDI风险显著相关(P = .027)。

临床怎么用

  • 常规量化并报告既往抗生素治疗可能改善经验性处方。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the relationship between cumulative, historical antibiotic therapy and the presence of ceftriaxone-resistant (CRO-R) Enterobacterales bloodstream infections (BSI) from urinary sources. METHODS: Adult patients established with primary care at Mayo Clinic with a first episode of monomicrobial Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, or Proteus mirabilis BSI from a urinary source from May 2019 to May 2023 were included. Antibiotic therapy over the year prior to BSI was quantified as days of therapy (DOT), cumulative modified Antibiotic Spectrum Index (mASI), and cumulative Days of Antibiotic Spectrum Coverage (DASC) using prescription data. Patients with CRO-R urinary pathogens prior to antibiotic therapy assessment were excluded. RESULTS: In total, 721 adults had monomicrobial gram-negative BSI, including 70 patients (9.7%) with a CRO-R pathogen and 651 patients (90.3%) with a ceftriaxone-susceptible (CRO-S) pathogen. In the 12 months prior to BSI, levels of antibiotic DOT, mASI, and DASC were significantly greater among patients with CRO-R BSI than CRO-S BSI (P < .001). The median time from blood culture collection to appropriate antibiotic therapy was significantly longer in the CRO-R group (24 hours, interquartile range [IQR] 16-48) than the CRO-S group (1 hour, IQR 0-2) (P < .001). Increasing cumulative antibiotic therapy prior to BSI, as quantified by the mASI, was significantly associated with increased risk of 1-year CDI after BSI (P = .027). CONCLUSIONS: Patients with first episode CRO-R Enterobacterales BSI had significantly greater prior antibiotic exposure than patients with CRO-S BSI and experienced significant delay of appropriate therapy. Routine quantitation and reporting of prior antibiotic therapy may improve empiric prescribing.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tande AJ, Stevens RW, Ilges D, et al. Cumulative Antibiotic Exposure Is Associated With Ceftriaxone Resistance Among Patients With Urinary Source Gram-negative Bloodstream Infection: A Retrospective Cohort Study. Clin Infect Dis. 2025. PMID: 40518932. doi:10.1093/cid/ciaf315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。